In an experimental model of diabetic nephropathy, rubositoline has been shown to normalize glomerular hyperfiltration by inhibiting PKC-β, reduce urinary albumin excretion, maintain renal function, and mitigate mesangial dilation, glomerular sclerosis, and tubulointerstitial fibrosis. Here, ALB is linked to diabetic kidney disease.